E. Costa, G. Racagni (Eds.) (1992). Typical and Atypical Antidepressants:Molecular
Mechanisms. Advances in Biochemical Psychopharmacology, vol. 31. New York: Raven
Press.
A. Davis (1984). Molecular aspects of the imipramine “receptor.”Experientia 40: 782–794.
J. D. Fitzgerald (1993). Do partial agonist β-blockers have improved clinical utility? Cardiovasc.
Drugs Ther. 7: 303.
S. Goldstein (1996). β-Blockers in hypertensive and coronary heart disease. Arch. Int. Med. 156:
1267.
R. M. Graham (1996). Alpha-1-adrenergic receptor subtypes: molecular structure, function and
signaling.Circ. Res. 78: 737.
P. Guicheney, P. Meyer (1979). Biochemical approach to pre- and postsynaptic α-adrenoceptors.
Trends Pharmacol. Sci. 1: 69–71.
J. R. Hampton (1994). Choosing the right β-blocker. Drugs 48: 549.
M. P. Heintzen, B. E. Strauer (1994). Peripheral vascular effects of β-blockers. Eur. Heart J.
15 :2.
E. J. M. Helmreich, T. Pfeuffer (1985). Regulation of signal transduction by β-adrenergic hor-
mone receptors. Trends Pharmacol. Sci. 6: 438–443.
B. I. Hoffman, R. J. Lefkowitz (1980). Radioligand binding of adrenergic receptors: new insights
into molecular and physiological regulation. Annu. Rev. Pharmacol. Toxicol. 20: 591–608.
P. A. Insel, R. D. Feldman (2004). Norepinephrine receptors. Encyclopedia of Endocrine
Diseases 3: 375–381.
G. Kolata (1987). Manic-depression gene tied to chromosome 11. Science 235: 1139–1140.
W. Kostowski (1981). Brain noradrenalin, depression and antidepressant drugs: facts and
hypotheses.Trends Pharmacol. Sci. 2: 314–317.
S. Z. Langer (1981). Presynaptic receptors. Pharmacol. Rev. 32: 337–363.
S. Z. Langer, C. Moret, R. Raisman, M. L. Dubocovich, M. Briley (1980). High-affinity^3 H-
imipramine binding in rat hypothalamus: association with uptake of serotonin but not nor-
epinephrine.Science 210: 1133–1135.
R. J. Lefkowitz, J. L. Benovic, B. Kobilka, M. C. Caron (1986). β-Adrenergic receptors and
rhodopsin: shedding new light on an old subject. Trends Pharmacol. Sci. 7: 444–448.
S. B. Liggett (2003). Polymorphisms of adrenergic receptors: variations on a theme. Assay and
Drug Dev. Tech. 1: 317–326.
A. Lovitzki (1986). β-Adrenergic receptors and their mode of coupling to adenylate cyclase.
Physiol. Rev. 66: 819–854.
E. Malta, G. A. McPherson, C. Raper (1985). Selective β 1 -adrenoceptor agonists—fact or fiction?
Trends Pharmacol. Sci. 6: 400–403.
C. J. Ohnmacht, J. B. Malick, W. J. Frazee (1983). Antidepressants. Annu. Rep. Med. Chem. 18:
41–50.
S. M. Paul, B. Hulihan-Giblin, P. Skolnik (1982). (+)-Amphetamine binding to rat hypothalamus:
relation to anorectic potency of phenylethylamines. Science 218: 487–489.
M. T. Plascik, D. M. Perez (2001). α1-Adrenergic receptors: new insights and directions.
J. Pharmacol. Exp. Therap. 298: 403–410.
S. R. Post, H. K. Hammond, P. A. Insel (1999). Beta-adrenergic receptors and receptor signaling
in heart failure. Ann. Rev. Pharmacol. Toxicol. 39: 343.
R. R. Ruffolo, J. P. Hieble (1994). α-Adrenoceptors.Pharmacol. Ther. 61:1.
R. Schorr, R. J. Lefkowitz, M. G. Caron (1981). Purification of the β-adrenergic receptor: iden-
tification of the hormone binding subunit. J. Biol Chem. 256: 5820–5826.
K. M. Small, D. W. McGraw, S. B. Liggett (2003). Pharmacology and physiology of human
adrenergic receptor polymorphisms. Ann. Rev. Pharmacol. Toxicol. 43: 381–411.
R. D. Smith, J. R. Regan (1986). Antihypertensive agents. Annu. Rev. Med. Chem. 21: 63–72.
NEUROTRANSMITTERS AND THEIR RECEPTORS 301